Detalhe da pesquisa
1.
In Vitro Anti-Tubulin Activity on MCF10A Cell Line and In Silico Rigid/Semiflexible-Residues Docking, of Two Lignans from Bursera Fagaroides var. Fagaroides.
Molecules
; 26(20)2021 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34684736
2.
Alternative Splicing as a Target for Cancer Treatment.
Int J Mol Sci
; 19(2)2018 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439487
3.
Mitochondrial dynamics and cancer.
Tumour Biol
; 39(5): 1010428317698391, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468591
4.
Drug repurposing of mito-atovaquone for cancer treatment.
Pharm Pat Anal
; 12(4): 143-149, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801038
5.
Estrogens as a Possible Therapeutic Strategy for the Management of Neuroinflammation and Neuroprotection in COVID-19.
Curr Neuropharmacol
; 21(10): 2110-2125, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37326113
6.
Drug repurposing of adapalene for melanoma treatment.
Pharm Pat Anal
; 11(1): 9-14, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35168402
7.
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents.
Expert Opin Drug Discov
; 17(12): 1341-1355, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399656
8.
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment.
Pharm Pat Anal
; 2021 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875853
9.
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.
Pharm Pat Anal
; 10(2): 67-72, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829869
10.
OX40 agonists for cancer treatment: a patent review.
Expert Opin Ther Pat
; 31(1): 81-90, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945223
11.
Molecular diagnosis of breast cancer: prognostic and therapeutic implications. / Diagnóstico molecular del cáncer de mama: implicaciones pronósticas y terapéuticas.
Rev Med Inst Mex Seguro Soc
; 58(Supl 1): S62-S74, 2020 04 27.
Artigo
em Espanhol
| MEDLINE | ID: mdl-34695317
12.
Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739.
Expert Opin Ther Pat
; 30(5): 307-311, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32106724
13.
Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
Expert Opin Ther Pat
; 30(2): 83-86, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31874056
14.
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
Expert Opin Ther Pat
; 29(7): 481-485, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31216214
15.
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1.
Expert Opin Ther Pat
; 29(5): 311-314, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30990738
16.
Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Expert Opin Ther Pat
; 29(12): 921-924, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31627712
17.
LAG-3 antagonists by cancer treatment: a patent review.
Expert Opin Ther Pat
; 29(8): 643-651, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291131
18.
Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
Recent Pat Anticancer Drug Discov
; 14(1): 85-94, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30381087
19.
Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
Expert Opin Ther Pat
; 29(8): 587-593, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31241380
20.
Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment.
Front Oncol
; 9: 480, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31231612